Zhejiang Hisun Pharmaceutical Co. Ltd. and Shanghai Aryl Pharmtech Co. Ltd. have disclosed mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1) inhibitors reported to be useful for the treatment of systemic lupus erythematosus, psoriasis, inflammation and cancer.

Beijing Innocare Pharma Tech Co. Ltd. has presented GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer.

Shanghai Meiyue Biotech Development Co. Ltd. has identified macrocyclic compounds acting as coagulation factor XIa (FXIa) inhibitors reported to be useful for the treatment of thrombosis.

Tsinghua University has patented compounds acting as GTPase KRAS (G12D mutant)...

Impact Therapeutics (Shanghai) Inc. has presented poly(ADP-ribose) polymerase (PARP) inhibitors reported to be useful for the treatment of cancer.

Erasca Inc. has identified GTPase KRAS (Gly12Asp mutant) inhibitors reported to be useful for the treatment of cancer.

Cnpharm Co. Ltd. has described conjugates comprising docetaxel and aconitic anhydride reported to be useful for the treatment of cancer.

Biocryst Pharmaceuticals Inc. has divulged kallikrein 5 (KLK5) inhibitors reported to be useful for the treatment of Netherton syndrome.

Eleusis Therapeutics US Inc. has synthesized aryl-ring-substituted 3-phenylazetidines acting as 5-HT2 receptor ligands reported to be useful for the treatment of chronic pain, depression, atherosclerosis, chronic obstructive pulmonary disease, conjunctivitis, type 2 diabetes, multiple sclerosis and rheumatoid arthritis, among others.

BioWorld MedTech presents Patent Highlights, an excerpt of the most important med-tech patents from this week's Cortellis Patents Gazette.